A
Angela M. Minassian
Researcher at University of Oxford
Publications - 68
Citations - 11967
Angela M. Minassian is an academic researcher from University of Oxford. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 25, co-authored 51 publications receiving 6156 citations. Previous affiliations of Angela M. Minassian include John Radcliffe Hospital & Nuffield Orthopaedic Centre.
Papers
More filters
Posted ContentDOI
Superior antibody immunogenicity of a RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
Sarah E. Silk,W. F. Kalinga,I. M. Mtaka,Maximillian Mpina,Florence A. Milando,Sara Ahmed,Ababacar Diouf,Beatus Simon,Thabit Athumani,Muzamil Rashid,L. Mohammed,Omar Lweno,A M Ali,Gloria Nyaulingo,Bakari Mwalimu,Sarah Mswata,T. Mwamlima,Jordan R. Barrett,Lu Wang,Yrene Themistocleous,Lloyd King,Susanne H. Hodgson,Ruth O. Payne,Carolyn M. Nielsen,Alison M. Lawrie,Fay L. Nugent,J.‐S. Cho,Carole A. Long,Kazutoyo Miura,Simon J. Draper,Angela M. Minassian,Ally Olotu +31 more
TL;DR: In this paper , a Phase 1b, single-center, dose-escalation, age deescalation and double-blind, randomized, controlled trial was conducted in Bagamoyo, Tanzania, where healthy adults (18-35 years), young children (1-6 years) and infants (6-11 months) were recruited to receive a priming dose of viral-vectored ChAd63 RH5 followed by a booster dose of MVA RH5 (or rabies control vaccine) 8 weeks later.
Journal ArticleDOI
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
Xinxue Liu,Alasdair Munro,Anne Wright,Shuo Feng,Leila Janani,Parvinder K. Aley,Gavin Babbage,Jonathan R. Baker,D. Baxter,Tanveer Bawa,Marcin D Bula,Katrina Cathie,Krishna Chatterjee,Kate Dodd,Y. Enever,Lauren M. Fox,EH Qureshi,Anna Goodman,Christopher A Green,John Haughney,Alexander Hicks,Christine E. Jones,Nasir Kanji,Agatha A. van der Klaauw,Vincenzo Libri,Martin J. Llewelyn,R I Mansfield,Mina H. Maallah,Alastair C McGregor,Angela M. Minassian,P. Moore,M Z Mughal,Y Mujadidi,Hanane Belhadef,Kyra Holliday,Orod Osanlou,Rostam Osanlou,Daniel R Owens,Mihaela Pacurar,Adrian Palfreeman,Daniel Pan,Tommy Rampling,Karen Regan,Stephen Saich,Dinesh Saralaya,Sunil Sharma,R Sheridan,Matthew Stokes,E. Thomson,Shirley Todd,Chris Twelves,Robert C. Read,Sue Charlton,Bassam Hallis,M. Ramsay,Nick Andrews,Teresa Lambe,Jonathan S. Nguyen-Van-Tam,Victoria Cornelius,Matthew D. Snape,Saul N. Faust +60 more
TL;DR: The COV-BOOST trial as mentioned in this paper compared the immunogenicity and kinetics of responses to third doses of vaccines from day (D) 28 to D242 following third doses in seven study arms.
Posted ContentDOI
Parasite species regulates T cell activation in human malaria
Florian Bach,Munoz Sandoval D,Munoz Sandoval D,M Mazurczyk,Yrene Themistocleous,Thomas A. Rawlinson,Alison Kemp,Sarah E. Silk,Barrett,Nick J. Edwards,Alasdair Ivens,Julian C. Rayner,Julian C. Rayner,Angela M. Minassian,Giorgio Napolitani,Simon J. Draper,Philip J Spence +16 more
TL;DR: The authors found that Plasmodium vivax triggers an acute phase response that shares remarkable overlap with that of P. falciparum, suggesting a hardwired innate response that does not differentiate between parasite species.
Journal ArticleDOI
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial
Eimear Kelly,Melanie Greenland,Philip C.S. De Whalley,Parvinder K. Aley,E Plested,Nisha Kumari Singh,S. Koleva,Sharon Tonner,Robert C. Read,Mary Ramsay,J. Claire Cameron,David P. J. Turner,Paul T. Heath,Jolanta Bernatoniene,Philip Connor,Katrina Cathie,Saul N. Faust,Indraneel Banerjee,L. Cantrell,Y Mujadidi,Hanane Belhadef,Elizabeth A. Clutterbuck,R. C. Anslow,Zara Valliji,Tim James,Bassam Hallis,Ashley Otter,Teresa Lambe,Jonathan S. Nguyen-Van-Tam,Angela M. Minassian,Xinxue Liu,Matthew D. Snape +31 more
TL;DR: The first study to investigate the reactogenicity and immunogenicity of COVID-19 vaccine regimens in adolescents was conducted in this article , where a phase II, single-blind, multi-centre, randomised-controlled trial recruited across seven UK sites from September to November 2021, with follow-up visits to August 2022.